RARE
Price
$27.34
Change
+$0.04 (+0.15%)
Updated
Jul 25 closing price
Capitalization
2.58B
4 days until earnings call
SONN
Price
$3.99
Change
-$0.23 (-5.45%)
Updated
Jul 25 closing price
Capitalization
24.99M
Interact to see
Advertisement

RARE vs SONN

Header iconRARE vs SONN Comparison
Open Charts RARE vs SONNBanner chart's image
Ultragenyx Pharmaceutical
Price$27.34
Change+$0.04 (+0.15%)
Volume$1.25M
Capitalization2.58B
Sonnet BioTherapeutics Holdings
Price$3.99
Change-$0.23 (-5.45%)
Volume$694.67K
Capitalization24.99M
RARE vs SONN Comparison Chart in %
Loading...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RARE vs. SONN commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RARE is a Hold and SONN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (RARE: $27.34 vs. SONN: $3.99)
Brand notoriety: RARE and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RARE: 63% vs. SONN: 13%
Market capitalization -- RARE: $2.58B vs. SONN: $24.99M
RARE [@Biotechnology] is valued at $2.58B. SONN’s [@Biotechnology] market capitalization is $24.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RARE’s FA Score shows that 0 FA rating(s) are green whileSONN’s FA Score has 0 green FA rating(s).

  • RARE’s FA Score: 0 green, 5 red.
  • SONN’s FA Score: 0 green, 5 red.
According to our system of comparison, SONN is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RARE’s TA Score shows that 4 TA indicator(s) are bullish while SONN’s TA Score has 4 bullish TA indicator(s).

  • RARE’s TA Score: 4 bullish, 5 bearish.
  • SONN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both RARE and SONN are a bad buy in the short-term.

Price Growth

RARE (@Biotechnology) experienced а +3.91% price change this week, while SONN (@Biotechnology) price change was -35.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.59B) has a higher market cap than SONN($25M). SONN YTD gains are higher at: 173.288 vs. RARE (-35.013). SONN has higher annual earnings (EBITDA): -13.69M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. SONN (2.06M). SONN has less debt than RARE: SONN (90.4K) vs RARE (38.3M). RARE has higher revenues than SONN: RARE (591M) vs SONN (1M).
RARESONNRARE / SONN
Capitalization2.59B25M10,340%
EBITDA-449.9M-13.69M3,285%
Gain YTD-35.013173.288-20%
P/E RatioN/A0.29-
Revenue591M1M59,100%
Total Cash494M2.06M23,992%
Total Debt38.3M90.4K42,367%
FUNDAMENTALS RATINGS
RARE vs SONN: Fundamental Ratings
RARE
SONN
OUTLOOK RATING
1..100
597
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9334
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (74) in the Biotechnology industry is in the same range as SONN (84) in the null industry. This means that RARE’s stock grew similarly to SONN’s over the last 12 months.

RARE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SONN (100) in the null industry. This means that RARE’s stock grew similarly to SONN’s over the last 12 months.

RARE's SMR Rating (100) in the Biotechnology industry is in the same range as SONN (100) in the null industry. This means that RARE’s stock grew similarly to SONN’s over the last 12 months.

SONN's Price Growth Rating (34) in the null industry is somewhat better than the same rating for RARE (93) in the Biotechnology industry. This means that SONN’s stock grew somewhat faster than RARE’s over the last 12 months.

SONN's P/E Growth Rating (96) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that SONN’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RARESONN
RSI
ODDS (%)
Bullish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 13 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
80%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IJSSX13.960.10
+0.72%
VY® JPMorgan Small Cap Core Equity S
JGRJX40.190.20
+0.50%
JPMorgan Growth Advantage R2
PJDAX18.450.06
+0.33%
PGIM Jennison Rising Dividend A
SZCRX52.860.05
+0.09%
DWS Small Cap Core R6
TCREX18.02-0.01
-0.06%
Nuveen Real Estate Sec Sel A

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with MREO. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+0.15%
MREO - RARE
66%
Loosely correlated
+1.15%
SNDX - RARE
48%
Loosely correlated
-3.60%
IMVT - RARE
46%
Loosely correlated
-7.48%
NRIX - RARE
46%
Loosely correlated
-0.09%
REPL - RARE
46%
Loosely correlated
+1.61%
More

SONN and

Correlation & Price change

A.I.dvisor indicates that over the last year, SONN has been closely correlated with PTHS. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SONN jumps, then PTHS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-5.45%
PTHS - SONN
70%
Closely correlated
-0.05%
SNBIF - SONN
28%
Poorly correlated
N/A
KOD - SONN
26%
Poorly correlated
+7.15%
RARE - SONN
25%
Poorly correlated
+0.15%
PRME - SONN
25%
Poorly correlated
-3.22%
More